News
RNA bundled in lipid nanoparticles trains T cells in mice to eliminate cancer. Coupled with noninvasive imaging, researchers ...
During a live event, Jorge Monge, MD, discussed short and long-term adverse events associated with CAR T-cell therapy in ...
The deal, announced on June 30, will advance a subsect of research into new autoimmune treatments that began at Penn.
Dr. Olalekan O. Oluwole explained how CAR T is used to treat high-risk blood cancers and highlighted the potential of ...
Real-world analysis reveals that undetectable CD20 expression worsens outcomes for patients treated with epcoritamab and ...
Researchers sought to determine whether dual-targeted CAR-T therapy would be effective for patients with relapsed or refractory MCL.
Anixa Biosciences' breast cancer vaccine elicited targeted immune responses in 70% of patients. Click here to read an ...
Mayo Clinic researchers have discovered a key reason some cancer patients relapse after receiving chimeric antigen receptor T ...
Explore the latest advancements in immunotherapies for T-cell lymphoma, addressing unique challenges and promising new ...
The OUTREACH Study – Demonstrating that CAR-T therapies can be effectively administered in community cancer settings: In the ...
The newly approved linvoseltamab (Lynozyfic; Regeneron) has a manageable safety profile, along with a patient-friendly dosing schedule that includes intravenous administration, step-up dosing, and ...
12d
The Times of Israel on MSNZelig Eshhar, leading cancer researcher and immunologist, dies at 84Research by Weizmann Institute scientist and Israel Prize winner saved 'countless lives,' was basis for technology sold for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results